Indaptus Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $317.04M
- P/E (TTM)
- –
- Dividend yield
- –
About Indaptus Therapeutics
Pharmaceutical Preparations, SIC 2834
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company that creates systemically administered immunotherapies to treat cancer and viral infections. The company develops technologies utilizing attenuated and killed, non-pathogenic Gram-negative bacteria to stimulate innate and adaptive immune defenses through intravenous administration. Its primary clinical candidate is Decoy20, an investigational agent evaluated for individuals with advanced solid tumors who have exhausted standard approved therapies. The company focuses on developing treatments intended for oncology patients and healthcare professionals addressing complex malignancies.
The company maintains its principal executive offices in New York, New York, and operates through subsidiaries that include Intec Pharma Ltd. and Decoy Biosystems, Inc. Its organizational footprint centers on biopharmaceutical research and corporate administration. While the firm previously evaluated its lead candidate in clinical trials, it has halted participant enrollment across these programs and currently has no active trial subjects.
Summary of the business section of Indaptus Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Indaptus Therapeutics, Inc.
- Headquarters
- New York, NY
- Address
- 3 Columbus Circle, 15th Floor 10019
- Phone
- (646) 427-2727
- Website
- indaptusrx.com
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Haskell & White LLP, Irvine, California
Stock & identifiers
- Ticker
- INDP
- Exchange
- Nasdaq
- IPO date
- Aug 4, 2015
- Shares outstanding
- 133M, Aug 13, 2026
- Public float
- $5.78M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-28.5 reverse, Aug 13, 2025; 1-for-28 reverse, Jun 27, 2025; 1-for-4 reverse, Jul 27, 2021; 1-for-20 reverse, Oct 30, 2020
- SEC CIK
- 1857044
- CUSIP
- 45339J204
- ISIN
- US45339J2042
- EIN
- 86-3158720
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jeffrey A. Meckler | Co-Chief Executive Officer, Director | 229,929 |
| Michael James Newman | CSO and Director | 1,469,430 |
| Junyi Dai | Chief Executive Officer | 11,250,000 |
| Walt Addison Linscott | Chief Operating Officer | 54,426 |
| Nir Sassi | Chief Financial Officer | 26,758 |
| Qinglai Lu | Director | – |
| David E. Lazar | Director | 0 |
| Jerome D. Jabbour | Director | – |
| Matthew Charles McMurdo | Director | 25,000 |
| Avraham Ben-Tzvi | Director | 25,100 |
| David Natan | Director | 0 |
| Hila Karah | Director | – |
| Mark John Gilbert | Director | – |
| Anthony J. Maddaluna | Director | 670 |
| Roger Pomerantz | Director | – |
| Robert Martell | Director | – |
| William B. Hayes | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jeffrey A. Meckler | $2.20M | $2.09M | $1.82M | $12 | – |
| FY2024 Jeffrey A. Meckler | $1.16M | $1.03M | $949.64K | $48 | – |
| FY2023 Jeffrey A. Meckler | $1.00M | $1.12M | $744.04K | $121 | – |
| FY2022 Jeffrey A. Meckler | $1.68M | -$38.39K | $1.06M | $25 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had five full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 31, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 16, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 6, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 6, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 6, 2021 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 3, 2021 | Name change | Name changed from Intec Parent Inc. to Indaptus Therapeutics, Inc. |
| Jul 29, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 20, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |